1-(2,5-二氟苯基)哌嗪 | 255893-33-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2,5-二氟苯基)哌嗪
• 英文名称: 1-(2,5-difluorophenyl)piperazine
• CAS: 255893-33-5
• 化学式: C₁₀H₁₂F₂N₂
• mdl: MFCD11872820
• 分子量: 198.215
• InChiKey: SWQMPOXIMTYXHI-UHFFFAOYSA-N

物化性质

• 沸点：
  296.5±40.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  4

制备方法与用途

该产品用于科研用途，作为研究中的化合物。

反应信息

• 作为反应物：
  描述：

  1-(2,5-二氟苯基)哌嗪 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 N-[2-[4-(2,5-difluorophenyl)piperazin-1-yl]-2-oxoethyl]isoquinoline-5-sulfonamide
  参考文献：
  名称：

  From Tyrosine to Glycine:  Synthesis and Biological Activity of Potent Antagonists of the Purinergic P2X₇ Receptor

  摘要：

  The characterization of the native and recombinant P2X(7) receptor continues to be hindered by the lack of specific and subtype-selective antagonists with a "druglike" profile. However, a tyrosine derivative named KN-62 exhibits selective P2X(7) receptor-blocking properties. As a molecular simplification of KN-62, the present study was designed to evaluate the functional antagonistic properties of a novel series of glycine derivatives characterized by the presence of different phenyl-substituted piperazine moieties. Antagonistic activity of these glycine derivatives was tested on HEK293 cells transfected with the human P2X(7) receptor. The most potent P2X(7) receptor antagonist identified in this study (compound 4g) contains an o-fluorine substituent on the phenylpiperazine moiety and had an IC50 of 12.1 nM. The biological responses investigated were ATP-dependent Ca2+ influx across the plasma membrane and ethidium bromide uptake.

  DOI：

  10.1021/jm070443e
• 作为产物：
  描述：

  2,5-二氟苯胺 、 二(2-氯乙基)胺盐酸盐 以40%的产率得到1-(2,5-二氟苯基)哌嗪
  参考文献：
  名称：

  Practical Method for Parallel Synthesis of Diversely Substituted 1- henylpiperazines

  摘要：

  已经开发出一种简单实用的方法，用于制备以替代1-苯基哌嗪构建块为内容的“库”，采用并行格式。

  DOI：

  10.2174/157017811799304386

文献信息

• Compounds specific for the human alpha1d adrenergic receptor and uses thereof
  申请人：——

  公开号：US20020028760A1

  公开（公告）日：2002-03-07

  This invention is directed towards a method of inhibiting activation of a human &agr; 1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human ald adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr; 1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr; 1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.

  这项发明涉及一种抑制人类α1d肾上腺素受体激活的方法，包括将受体与一种化合物接触，以抑制受体的激活，其中该化合物选择性地结合到人类α1d肾上腺素受体。这项发明提供了一种选择性结合到人类α1d肾上腺素受体的化合物。该发明还提供了一种包含上述定义的化合物的治疗有效量和药学上可接受的载体的药物组合物。这项发明还提供了一种治疗患有易受人类α1d肾上腺素受体拮抗治疗的疾病的方法，包括向受试者施用上述定义的化合物的有效量以治疗疾病。
• Hydroxamic acid derivatives as metalloprotease inhibitors
  申请人：Burns M. David

  公开号：US20050250789A1

  公开（公告）日：2005-11-10

  The present invention provides compounds of Formula I or II: salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for example, arthritis, cancer, cardiovascular disorders, skin disorders, inflammation or allergic conditions.

  本发明提供了Formula I或II的化合物： 盐形式或其前药，其中变量在此处定义，这些化合物是金属蛋白酶调节剂，如基质金属蛋白酶（MMPs）和ADAMs。本文描述的化合物或组合物可用于治疗与金属蛋白酶活性相关的疾病，包括例如关节炎、癌症、心血管疾病、皮肤疾病、炎症或过敏症状。
• Iridium-Catalyzed Asymmetric Ring-Opening Reactions of Oxabenzonorbornadienes with Amine Nucleophiles
  作者：Dingqiao Yang、Yuhua Long、Junfang Zhang、Heping Zeng、Sanyong Wang、Chunrong Li

  DOI：10.1021/om100384q

  日期：2010.8.23

  We have explored a new iridium-catalyzed ring-opening reaction of oxabenzonorbornadienes with a variety of primary aromatic amine or N-substituted piperazine nucleophiles, affording the corresponding products in excellent yields (up to 99%) with moderate enantioselectivity (25−81% ee). The trans configuration of product 2d was confirmed by X-ray crystallography.

  我们探索了氧杂苯并降冰片二烯与各种伯芳族胺或N-取代的哌嗪亲核试剂的铱催化开环反应，从而以中等收率（25-81％ee）以优异的收率（高达99％）提供了相应的产物）。通过X射线晶体学确认产物2d的反式构型。
• [EN] COMPOUNDS SPECIFIC FOR THE HUMAN alpha 1d ADRENERGIC RECEPTOR AND USES THEREOF<br/>[FR] COMPOSES SPECIFIQUES DU RECEPTEUR ADRENERGIQUE alpha 1d HUMAIN ET SES UTILISATIONS
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2000004012A1

  公开（公告）日：2000-01-27

  This invention is directed towards a method of inhibiting activation of a human α1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human α1d adrenergic receptor. This invention provides for a compound which binds selectively to a human α1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human α1d adrenergic receptor which comprises administering to the subject an amount of the above defined compound to treat the disease.

  本发明涉及一种抑制人类α1d肾上腺素能受体激活的方法，其中包括将化合物与受体接触以抑制受体的激活，所述化合物选择性地结合于人类α1d肾上腺素能受体。本发明提供了一种选择性结合于人类α1d肾上腺素能受体的化合物。本发明还提供了一种包含上述定义化合物的治疗有效量和药学上可接受的载体的制剂。本发明还提供了一种治疗患有可通过对抗人类α1d肾上腺素能受体治疗的疾病的受试者的方法，其中包括向受试者施用上述定义化合物的量以治疗疾病。
• Compounds specific for the human &agr;1d adrenergic receptor and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06706716B2

  公开（公告）日：2004-03-16

  This invention is directed towards a method of inhibiting activation of a human &agr;1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human &agr;1d adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr;1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr;1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.

  本发明涉及一种抑制人类α1d肾上腺素能受体激活的方法，该方法包括将化合物与受体接触以抑制其激活，其中该化合物选择性地结合于人类α1d肾上腺素能受体。本发明提供了一种选择性结合于人类α1d肾上腺素能受体的化合物。本发明还提供了一种制药组合物，包括上述定义的化合物的治疗有效量和药学可接受载体。本发明还提供了一种治疗易受人类α1d肾上腺素能受体拮抗剂治疗的疾病的方法，该方法包括向患者施用上述定义的化合物的有效治疗量以治疗该疾病。